Literature DB >> 8448706

Technology assessment and cost-effectiveness analysis: misguided guidelines?

C D Naylor1, J I Williams, A Basinski, V Goel.   

Abstract

Keywords:  Health Care and Public Health

Mesh：

Year:  1993        PMID： 8448706      PMCID： PMC1490754     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

1.  Applications of cost-benefit analysis to health care. Departures from welfare economic theory.

Authors:  S Birch; C Donaldson
Journal:  J Health Econ       Date:  1987-09       Impact factor: 3.883

2.  Incorporating variations in the quality of individual randomized trials into meta-analysis.

Authors:  A S Detsky; C D Naylor; K O'Rourke; A J McGeer; K A L'Abbé
Journal:  J Clin Epidemiol       Date:  1992-03       Impact factor: 6.437

3.  Health care technology assessment: linking science and policy-making.

Authors:  R N Battista
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

4.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

5.  Where to draw the line against cholesterol.

Authors:  A M Garber
Journal:  Ann Intern Med       Date:  1989-10-15       Impact factor: 25.391

6.  Quality-adjusted life-years. Ethical implications for physicians and policymakers.

Authors:  J La Puma; E F Lawlor
Journal:  JAMA       Date:  1990-06-06       Impact factor: 56.272

7.  Rules of evidence and clinical recommendations on the use of antithrombotic agents.

Authors:  D L Sackett
Journal:  Chest       Date:  1989-02       Impact factor: 9.410

8.  Economic analysis and clinical trials.

Authors:  M F Drummond; G L Stoddart
Journal:  Control Clin Trials       Date:  1984-06

9.  Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.

Authors:  V Goel; C D Naylor
Journal:  Can J Cardiol       Date:  1992 Jan-Feb       Impact factor: 5.223
  9 in total
  8 in total

1.  Ontario's formulary committee: how recommendations are made.

Authors:  Anne M PausJenssen; Peter A Singer; Allan S Detsky
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  Multi-attribute preference functions. Health Utilities Index.

Authors:  G W Torrance; W Furlong; D Feeny; M Boyle
Journal:  Pharmacoeconomics       Date:  1995-06       Impact factor: 4.981

3.  The emerging government requirement for economic evaluation of pharmaceuticals.

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 4.  Interpretation of cost-effectiveness analyses.

Authors:  D K Owens
Journal:  J Gen Intern Med       Date:  1998-10       Impact factor: 5.128

5.  Guidelines for writing guidelines.

Authors:  W R Harris
Journal:  CMAJ       Date:  1994-09-01       Impact factor: 8.262

6.  Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program.

Authors:  M Krahn; R Guasparini; M Sherman; A S Detsky
Journal:  Am J Public Health       Date:  1998-11       Impact factor: 9.308

7.  Postoperative pain management--back to basics.

Authors:  C A Moote
Journal:  Can J Anaesth       Date:  1995-06       Impact factor: 5.063

Review 8.  Technology assessment of anaesthesia monitors: problems and future directions.

Authors:  R J Byrick; M M Cohen
Journal:  Can J Anaesth       Date:  1995-03       Impact factor: 5.063
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.